Clinical Trials Logo
  1. Home
  2. Liver Metastasis
  3. NCT01511146

Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor

Liver Metastasis Clinical Trial

Official title:
Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors

Clinical Trial Summary

The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases. If the patients have colorectal cancer and never had got chemotherapy the investigators will use oxaliplatin together with capecitabine. If the patient is K-RAS wild type the investigators will add cetuximab. In patients who had received oxaliplatin or in patients with other cancers the investigators will use mitomycin and gemcitabine together with capecitabine.

Clinical Trial Description

Two regiment are used: N.B. The two regiments will be reported separately

1. Mitomycin + Gemcitabine intrahepatic together with Capecitabine. This treatment can be offered patients with solid tumors where all standard treatments have been used. The patients are not allowed to have extrahepatic disease. The purpose of the treatment are to prolonged life.

2. FOLFOX where oxaliplatin is given intrahepatic each second time. The treatment are only for patients with colorectal cancer where cure is possible but resection straight ahead is not possible. The patients are allowed to have their colorectal cancer in situ for operation latter on. If the patients are KRAS Wild-type, cetuximab are added. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01511146
Study type Interventional
Source Copenhagen University Hospital at Herlev
Contact
Status Recruiting
Phase Phase 2
Start date July 2011
Completion date July 2016
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05524155 - Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Phase 2
Recruiting NCT02632201 - Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis Phase 1/Phase 2
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Recruiting NCT01035385 - Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC) Phase 3
Recruiting NCT05098847 - Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors Phase 2
Withdrawn NCT02651090 - Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI Phase 3
Withdrawn NCT01775280 - Response of Hepatic Tumors to Radioembolization Phase 2
Completed NCT00068068 - Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases Phase 2
Terminated NCT02453490 - Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis Phase 3
Recruiting NCT04622423 - Advanced Therapies for Liver Metastases
Completed NCT00892424 - Sorafenib-RT Treatment for Liver Metastasis (SLIM) Phase 1/Phase 2
Completed NCT00028405 - Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Phase 1
Completed NCT03801915 - Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Phase 2
Completed NCT02218801 - A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
Completed NCT01834014 - Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases N/A
Completed NCT00083785 - Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases Phase 2
Active, not recruiting NCT03428477 - EPA for Metastasis Trial 2 Phase 3
Completed NCT02316028 - Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) Phase 1/Phase 2
Completed NCT01785212 - The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver N/A
Completed NCT03785210 - Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Phase 2